Profile data is unavailable for this security.
About the company
Kissei Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company operates through four segments. The Pharmaceutical segment manufactures and sells prescription drugs, and also purchases and sells healthcare foods such as prescription drugs and foods for special medical purposes. The Goods Sales segment is engaged in the development, production and sale of noodles, the sale of various equipment, vehicles and fuel, as well as insurance agency business. The Information Services segment operates in three areas including system integration services, system resource services such as information-related equipment rental and network construction, and medical system development and sales. The Construction and Facility Maintenance segment provides comprehensive construction services ranging from building construction to the maintenance and management of equipment and facilities.
- Revenue in JPY (TTM)95.29bn
- Net income in JPY14.14bn
- Incorporated1946
- Employees1.78k
- LocationKissei Pharmaceutical Co Ltd19-48, YoshinoMATSUMOTO-SHI 399-8710JapanJPN
- Phone+81 263259081
- Fax+81 263257899
- Websitehttps://www.kissei.co.jp
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Katakura Industries Co Ltd | 40.98bn | 5.84bn | 110.75bn | 941.00 | 17.25 | 1.10 | 12.59 | 2.70 | 182.30 | 182.30 | 1,278.51 | 2,853.06 | 0.2926 | 2.15 | 6.42 | 43,545,160.00 | 4.27 | 2.60 | 5.20 | 3.57 | 36.16 | 37.98 | 14.59 | 9.44 | 2.63 | -- | 0.0807 | 23.42 | -1.37 | -2.19 | 15.73 | 15.27 | -7.22 | 33.03 |
| Zeria Pharmaceutical Co Ltd | 86.61bn | 7.26bn | 113.13bn | 1.75k | 13.43 | 1.02 | 7.77 | 1.31 | 164.79 | 164.79 | 1,964.97 | 2,178.21 | 0.5366 | 1.27 | 3.21 | 49,607,640.00 | 4.49 | 4.67 | 6.99 | 7.47 | 72.76 | 72.17 | 8.37 | 9.02 | 0.9739 | 11.41 | 0.2984 | 28.75 | 15.30 | 7.64 | 28.52 | 27.71 | 16.51 | 6.69 |
| Mochida Pharmaceutical Co Ltd | 111.92bn | 6.42bn | 136.28bn | 1.51k | 20.67 | 0.966 | 14.52 | 1.22 | 181.16 | 181.16 | 3,156.95 | 3,876.77 | 0.6427 | 1.67 | 3.02 | 74,214,190.00 | 3.69 | 4.50 | 4.47 | 5.44 | 48.43 | 52.49 | 5.74 | 6.87 | 2.85 | -- | 0.0678 | 43.01 | 2.21 | 0.6516 | 25.03 | 4.34 | 1.98 | 0.00 |
| Kaken Pharmaceutical Co Ltd | 75.66bn | -3.83bn | 186.27bn | 1.13k | -- | 1.10 | -- | 2.46 | -97.11 | -97.11 | 1,980.56 | 3,850.39 | 0.4091 | 1.86 | 2.80 | 67,195,380.00 | -2.07 | 5.99 | -2.42 | 6.87 | 53.09 | 56.17 | -5.06 | 12.91 | 3.21 | -- | 0.0257 | 59.58 | 30.52 | 1.05 | 73.77 | -6.36 | 14.81 | 0.00 |
| Towa Pharmaceutical Co Ltd | 266.67bn | 20.65bn | 195.25bn | 4.79k | 9.04 | 1.04 | 4.64 | 0.7322 | 419.38 | 419.38 | 5,417.06 | 3,653.68 | 0.5776 | 1.51 | 4.12 | 55,694,650.00 | 4.47 | 3.89 | 5.45 | 5.07 | 36.38 | 37.81 | 7.74 | 6.61 | 1.51 | 44.31 | 0.5678 | 21.52 | 13.89 | 18.65 | 17.39 | 5.53 | 46.23 | 9.73 |
| Kissei Pharmaceutical Co Ltd | 95.29bn | 14.14bn | 215.49bn | 1.78k | 13.72 | 0.8869 | 11.41 | 2.26 | 337.47 | 337.47 | 2,274.29 | 5,220.29 | 0.3748 | 1.85 | 2.83 | 53,596,180.00 | 5.62 | 4.26 | 6.19 | 4.60 | 48.21 | 48.59 | 14.99 | 14.30 | 3.42 | -- | 0.0058 | 32.41 | 16.87 | 6.91 | 7.18 | 33.54 | 31.04 | 13.97 |
| Sawai Group Holdings Co Ltd | 200.00bn | 309.00m | 277.23bn | 3.31k | 3,774.31 | 1.57 | 17.42 | 1.39 | 0.636 | -11.40 | 1,703.92 | 1,531.41 | 0.5559 | 1.24 | 4.09 | 60,422,060.00 | 0.0862 | -0.2327 | 0.1143 | -0.3187 | 29.39 | 32.95 | 0.155 | -0.475 | 0.812 | 0.7435 | 0.3737 | 191.65 | 6.88 | 0.7009 | -87.38 | -35.38 | 8.65 | 4.11 |
| Tsumura & Co | 189.50bn | 29.01bn | 310.10bn | 4.27k | 10.44 | 0.9863 | 7.27 | 1.64 | 387.15 | 387.15 | 2,524.84 | 4,095.99 | 0.374 | 0.7106 | 2.41 | 44,357,680.00 | 6.01 | 5.53 | 8.06 | 6.85 | 47.60 | 49.39 | 16.06 | 14.50 | 1.45 | -- | 0.2856 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Holder | Shares | % Held |
|---|---|---|
| Brandes Investment Partners LPas of 30 Sep 2025 | 2.54m | 5.46% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 1.26m | 2.71% |
| Nomura Asset Management Co., Ltd.as of 08 Jan 2026 | 971.50k | 2.09% |
| JPMorgan Asset Management (Japan) Ltd.as of 31 Dec 2025 | 711.80k | 1.53% |
| Amundi Japan Ltd.as of 05 Feb 2026 | 595.00k | 1.28% |
| Amova Asset Management Co., Ltd.as of 09 Jan 2026 | 455.10k | 0.98% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 434.90k | 0.93% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 416.98k | 0.90% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 416.80k | 0.90% |
| Dimensional Fund Advisors LPas of 30 Nov 2025 | 381.71k | 0.82% |
